
Why Symprove Works

ARRIVE
​
Symprove's water-based formula arrives alive in the stomach.
​
THRIVE
​
Independent research by University College London found that Symprove was therefore more able to thrive in the gut than 7 other leading products
​
SURVIVE
And because it doesn't trigger digestion, it is more able to reach your gut.
Read on for independent studies & clinical trials on Symprove
(Don't just take our word)
Study #1: A challenge test of Symprove vs. other probiotics on their ability to Arrive, Survive & Thrive
-
An independent study by Dr Simon Gaisford at University College London (UCL) School of Pharmacy tested Symprove and 7 market-leading probiotics.
-
The study subjected the products to three challenge tests to assess if the bacteria ARRIVED in a live state, SURVIVED stomach acid transit and THRIVED in the target area of the gut.
-
Symprove was the only product to pass all three tests.
Study #2: A study to establish the efficacy of Symprove in irritable bowel syndrome (IBS)
-
This independent study was carried out at King’s College London by Dr Guy Sisson and Professor Ingvar Bjarnason to establish the efficacy of Symprove in irritable bowel syndrome (IBS).
-
The study was carried out on 186 IBS sufferers, mostly with moderate to severe symptoms. They each receive either a daily dose of Symprove or an identical placebo liquid for three months.
-
It concluded that a statistical significant improvement in overall symptom severity (in pain, bowel habit and bloating), was seen in IBS sufferers who took Symprove.

Study #3: A study to assess Symprove's efficacy in Inflammatory Bowel Disease (IBD)
-
In this double-blind, placebo-controlled trial 80 adults aged between 18 and 65-years-old with ulcerative colitis (who were all in remission at the time of the study starting) were randomised to receive either Symprove or a matching placebo drink for one month.
-
The study was carried out by Dr Guy Sisson, Dr Bu Hayee and Professor Ingvar Bjarnason of Darent Valley Hospital and King’s College London.
-
Faecal calprotectin levels were measured before and after treatment. Reductions in calprotectin levels (intestinal inflammation) were observed in the majority (76%) of patients with ulcerative colitis. The decrease in intestinal inflammation was significantly greater than in the placebo group.

Study #4: A study on Symprove and Diverticular Disease (DD)
-
In this double-blind, placebo-controlled trial 120 adults with moderate to severe diverticular disease (DD) were randomised to receive either Symprove or a matching placebo drink for three months.
-
The independent study was carried out at Kings College Hospital London by Dr Savvas Papagrigoriadis and Professor Ingvar Bjarnason.
-
The study concluded that Symprove had a significant benefit in the following:
-
Reduced the frequency of constipation, diarrhoea, mucorrhea and back pain
-
Prevented an escalation in inflammatory activity in males
-
Was associated with fewer diverticulitis episodes in a subgroup of patients.
-
